Last updated: 2026-10-09 05:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pulmonx Corporation (LUNG) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1,81, with a market capitalization of $76,45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,13 to $2,89. This page covers its latest market performance, valuation, price trends and company information.
$76,45M | |
$1,84 | |
$69,48 | |
$1,13 | |
$1,84 | |
154,65K | |
481,48K | |
-- | |
$2,89 | |
$1,13 | |
-- | |
-- |
Pulmonx Corporation (LUNG) last closed at $1,84 as of 2026-10-08 23:31:00, unchanged from the previous close of $1,84.
During the latest regular trading session, LUNG traded between $1,13 and $69,48, with a volume of 154,65K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Pulmonx Corporation (LUNG) moved from $1,98 to $1,81, representing a decline of 8,84% ($0,18).
The stock traded between $1,75 and $2,00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 245,05 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38,4%
LUNG is currently trading at $1,81, placing it 38,4% of the way from its 52-week low of $1,13 to its 52-week high of $2,89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 296 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pulmonx Corporation (LUNG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.